Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
June 3, 2024 4:03 PM EDTCiti analyst David Lebowitz reiterated a Neutral rating and $29.00 price target on Arrowhead Pharma (NASDAQ: ARWR)
The analyst comments "Plozasiran succeeded in Ph3 PALISADE trial in familial chylomicronemia syndrome (FCS), showing up to 80% triglyceride (TG) lowering at Month-10 at 25 and 50mg quarterly doses,... More
